Source:El sitio web de Dermatología de INFOMED, Portal de la Medicina en Cuba.http://www.sld.cu/sitios/dermatologia/
21 Marzo 2012
News Author: Troy Brown
CME Author: Hien T. Nghiem, MD
Faculty and Disclosures
CME Released: 03/05/2012; Valid for credit through 03/05/2013
CME Information Earn CME Credit »
Psoriasis is a difficult skin disease to treat and usually requires long-term use of systemic therapies to achieve adequate disease control. Multiple systemic therapies are currently available; however, unmet needs remain for safe and effective long-term psoriasis treatments. Psoralen plus ultraviolet A is associated with photo-aging and increased risks for cutaneous malignant diseases, whereas while ultraviolet B phototherapy has limited data. Long-term use of systemic therapies has been associated with cumulative end-organ toxicities (eg, hepatotoxicity with methotrexate and nephrotoxicity with cyclosporine).
Ustekinumab has been shown to be highly efficacious in the treatment of moderate to severe plaque psoriasis. Results of the Psoriasis Followed by Long-Term Extension (PHOENIX) 1 study reported to date have described the efficacy and safety of ustekinumab for psoriasis through week 76. The aim of this study by Kimball and colleagues was to evaluate the efficacy and safety of ustekinumab through 3 years in the PHOENIX 1 trial.
Study Synopsis and Perspective
Researchers have found that ustekinumab, a novel interleukin 12 (IL-12) and IL-23 antagonist, has a favorable benefit–risk profile for up to 3 years of treatment for moderate to severe psoriasis.
Alexandra Boer Kimball, MD, MPH, associate professor in the Department of Dermatology at Harvard Medical School in Boston, Massachusetts, and colleagues reported their findings in an article published online February 22 in the British Journal of Dermatology.
(!)Ustekinumab Safe, Effective in Long-Term Psoriasis Treatment… for up to 3 years of treatment for moderate to severe psoriasis. Alexandra Boer Kimball, MD, MPH, associate professor in the Department of …